Matt supports the Biopharma Journal Finance editorial team with reporting, research, and audience development. He was previously with WallStreet International in NYC.
In a major stride towards addressing bladder cancer, ImmunityBio, Inc. (NASDAQ: IBRX) has recently completed the manufacturing of a drug substance that...